MGBCI Breast Oncology shared on X:
“New in JAMA Oncology by Dr. Lis Ravani et al.
Do BICR and investigator assessments yield different PFS estimates in randomized trials of patients with HR+/ERBB2- metastatic breast cancer? Results suggest comparable PFS estimates with both approaches.”
Title: Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review – A Systematic Review and Meta-Analysis
Authors: Lis Victoria Ravani, Zahra Bagheri, Kevin Kalinsky, Harold J. Burstein, Aditya Bardia, Jason A. Mouabbi, Ruth O’Regan, Seth A. Wander
Read the full article.
